HCAT News & Events

Sees Q2 adjusted EBITDA $9M-$10M.

Sees FY26 adjusted EBITDA $30M-$33M.

Reports Q1 revenue $70.76M, consensus $69.19M. "We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations," said Ben Albert, Chief Executive Officer of Health Catalyst. "More importantly, this quarter we took the first decisive step toward transforming our operating model and aligning the company around its highest-conviction technology opportunities. This is not a short-term cost exercise. It is a strategic reset designed to build a more focused, durable Health Catalyst capable of meeting the opportunity in front of us. I am confident in the leadership team and board we have assembled to build the intelligence-driven technology company healthcare needs."

In a regulatory filing, the company said, "On April 24, 2026, the Board of Directors of Health Catalyst determined that Linda Llewelyn will cease to serve as the Chief People Officer of the company effective June 1, 2026 due to the elimination of the Chief People Officer role in connection with the workforce reduction described in this Current Report on Form 8-K. In order to enable a smooth transition of her prior responsibilities as Chief People Officer, the company and Ms. Llewelyn anticipate entering into a separation agreement and an independent contractor agreement pursuant to which Ms. Llewelyn is expected to serve as a senior advisor starting June 2, 2026 through September 1, 2026."